Drugs / HBV-MPL vaccine Formulation A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00697775 | Mar 1998 → May 1999 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBV-MPL vaccine Formulation A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697775 ↗ |
| Modality | Vaccine | “HBV-MPL vaccine Formulation A” NCT00697775 ↗ |
| Route | Intramuscular | “Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection” NCT00697775 ↗ |